New approaches for leprosy diagnosis and treatment
Treatments studied
Part of Infections clinical trials.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a newly diagnosed patient with multibacillary leprosy (a type that affects many parts of the body) and have a bacterial index between 1 and 6.
- Or you are a close contact of a leprosy patient, such as someone who lives in the same house, shares a kitchen, or is a direct neighbor.
- You must be willing to take part in the study and sign a consent form.
- You cannot have pure nerve leprosy (only affecting nerves) or be a paucibacillary patient (mild form with few bacteria).
- Contacts must be at least 5 years old, not pregnant, not on tuberculosis or leprosy treatment, and not have liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain genes (TGF beta 1) in people with leprosy who are already taking multidrug therapy. It aims to understand how these genes might affect the disease, which could lead to better treatments in the future.
This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).
This study looks at whether a specific gene (Rab 32) affects how leprosy progresses. It may help doctors better predict outcomes for people with leprosy.
This study tests a new way to diagnose leprosy by taking a tiny sample from a nerve under the skin using ultrasound guidance. The goal is to see if this method can accurately detect leprosy and help doctors know when treatment is working.
This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.